PillRx only · Injection, Solution · Subcutaneous
Ixekizumab
Brands: Taltz · Ixekizumab
1 ACTIVE SUPPLIER — US
openFDA · updated weekly
US4 NDCs
1 active makers
1 active makers
UKComing
soon
soon
CAComing
soon
soon
AUComing
soon
soon
EUComing
soon
soon
US acquisition costNADAC · per unit
Average across 4 priced NDCs. A benchmark of pharmacy acquisition cost — not a retail quote.
$7395.388
Latest avg · Jul 22, 2026
+5%
Since Jan 1, 2025
1
Active US suppliers
100%
Top-2 supplier share*
Medicaid dispensing volumeSDUD · per quarter
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume — Medicaid only, not all-payer.
33K
Rx · 2026 Q1
38K
Units dispensed
-12%
Rx vs. year ago
5
Quarters · since 2025 Q1
Who makes it1 active · 0 exited
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| Eli Lilly and Company | unknown | 8 | SUPPLYING |
Regulatory & supply events
No recalls, shortages, or registration changes on record for this drug concept.